vs
Side-by-side financial comparison of NovoCure Ltd (NVCR) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $174.1M, roughly 1.1× NovoCure Ltd). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs -40.9%, a 88.8% gap on every dollar of revenue. On growth, NovoCure Ltd posted the faster year-over-year revenue change (12.3% vs -21.9%). Over the past eight quarters, NovoCure Ltd's revenue compounded faster (7.6% CAGR vs -15.4%).
NovoCure Ltd is a global oncology company that develops and commercializes innovative Tumor Treating Fields (TTFields) therapy, a non-invasive wearable treatment using low-intensity electric fields to disrupt cancer cell division. Its approved therapies target glioblastoma, malignant mesothelioma and non-small cell lung cancer, serving patients across North America, Europe and Asia Pacific.
NVCR vs RILY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $174.1M | $188.3M |
| Net Profit | $-71.1M | $90.3M |
| Gross Margin | 77.6% | 79.5% |
| Operating Margin | — | 32.3% |
| Net Margin | -40.9% | 47.9% |
| Revenue YoY | 12.3% | -21.9% |
| Net Profit YoY | -107.3% | 1710.8% |
| EPS (diluted) | — | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $174.1M | — | ||
| Q4 25 | $174.3M | $188.3M | ||
| Q3 25 | $167.2M | $215.3M | ||
| Q2 25 | $158.8M | $188.2M | ||
| Q1 25 | $155.0M | $197.2M | ||
| Q4 24 | $161.3M | $241.0M | ||
| Q3 24 | $155.1M | $225.5M | ||
| Q2 24 | $150.4M | $256.0M |
| Q1 26 | $-71.1M | — | ||
| Q4 25 | $-24.5M | $90.3M | ||
| Q3 25 | $-37.3M | $91.1M | ||
| Q2 25 | $-40.1M | $139.5M | ||
| Q1 25 | $-34.3M | $-10.0M | ||
| Q4 24 | $-65.9M | $-5.6M | ||
| Q3 24 | $-30.6M | $-284.4M | ||
| Q2 24 | $-33.4M | $-433.6M |
| Q1 26 | 77.6% | — | ||
| Q4 25 | 75.8% | 79.5% | ||
| Q3 25 | 73.2% | 83.7% | ||
| Q2 25 | 73.9% | 81.3% | ||
| Q1 25 | 75.1% | 81.4% | ||
| Q4 24 | 79.2% | 79.8% | ||
| Q3 24 | 77.2% | 82.1% | ||
| Q2 24 | 77.0% | 84.5% |
| Q1 26 | — | — | ||
| Q4 25 | -23.2% | 32.3% | ||
| Q3 25 | -21.5% | 30.4% | ||
| Q2 25 | -24.9% | 5.7% | ||
| Q1 25 | -24.4% | -31.2% | ||
| Q4 24 | -39.3% | -69.2% | ||
| Q3 24 | -20.7% | -36.4% | ||
| Q2 24 | -22.3% | -90.8% |
| Q1 26 | -40.9% | — | ||
| Q4 25 | -14.1% | 47.9% | ||
| Q3 25 | -22.3% | 42.3% | ||
| Q2 25 | -25.3% | 74.1% | ||
| Q1 25 | -22.1% | -5.1% | ||
| Q4 24 | -40.9% | -2.3% | ||
| Q3 24 | -19.7% | -126.1% | ||
| Q2 24 | -22.2% | -169.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.22 | $2.78 | ||
| Q3 25 | $-0.33 | $2.91 | ||
| Q2 25 | $-0.36 | $4.50 | ||
| Q1 25 | $-0.31 | $-0.39 | ||
| Q4 24 | $-0.61 | $-0.01 | ||
| Q3 24 | $-0.28 | $-9.39 | ||
| Q2 24 | $-0.31 | $-14.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $432.0M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $330.7M | $-171.5M |
| Total Assets | $787.9M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $432.0M | — | ||
| Q4 25 | $93.5M | $226.6M | ||
| Q3 25 | $342.1M | $184.2M | ||
| Q2 25 | $149.6M | $267.4M | ||
| Q1 25 | $127.3M | $138.3M | ||
| Q4 24 | $163.8M | $146.9M | ||
| Q3 24 | $185.4M | $159.2M | ||
| Q2 24 | $164.8M | $236.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $330.7M | — | ||
| Q4 25 | $340.5M | $-171.5M | ||
| Q3 25 | $341.3M | $-260.5M | ||
| Q2 25 | $349.4M | $-351.7M | ||
| Q1 25 | $362.0M | $-496.8M | ||
| Q4 24 | $360.2M | $-488.2M | ||
| Q3 24 | $360.8M | $-497.6M | ||
| Q2 24 | $361.8M | $-218.3M |
| Q1 26 | $787.9M | — | ||
| Q4 25 | $804.3M | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.2B | $1.5B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $1.2B | $2.2B | ||
| Q2 24 | $1.2B | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $26.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.0M | $26.2M | ||
| Q3 25 | $20.6M | $-60.6M | ||
| Q2 25 | $-15.9M | $-25.6M | ||
| Q1 25 | $-35.7M | $184.0K | ||
| Q4 24 | $-3.5M | $-2.7M | ||
| Q3 24 | $10.4M | $19.5M | ||
| Q2 24 | $-1.7M | $111.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-22.9M | — | ||
| Q3 25 | $14.9M | — | ||
| Q2 25 | $-21.4M | — | ||
| Q1 25 | $-46.3M | — | ||
| Q4 24 | $-12.4M | — | ||
| Q3 24 | $-307.0K | — | ||
| Q2 24 | $-13.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -13.1% | — | ||
| Q3 25 | 8.9% | — | ||
| Q2 25 | -13.5% | — | ||
| Q1 25 | -29.9% | — | ||
| Q4 24 | -7.7% | — | ||
| Q3 24 | -0.2% | — | ||
| Q2 24 | -8.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | 7.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NVCR
Segment breakdown not available.
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
